{"id":"W2397619099","doi":"10.1016/j.critrevonc.2016.04.019","title":"Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program","year":2016,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Takeda Oncology","keywords":"Brentuximab vedotin; Tolerability; Medicine; Internal medicine; Oncology; Refractory (planetary science); Anaplastic large-cell lymphoma; Lymphoma; Clinical trial; Hodgkin lymphoma; Adverse effect","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002281131,0.0007670234,0.002719961,0.005987103,0.0002566061,0.001243345,0.001048853,0.0008065305,0.00216884],"category_scores_gemma":[0.004722411,0.0004035769,0.001617314,0.006900775,0.0003680845,0.001340758,0.0006668313,0.0008051662,0.0004081454],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009571115,"about_ca_system_score_gemma":0.003019838,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002282529,"about_ca_topic_score_gemma":0.00529579,"domain_scores_codex":[0.9990157,0.0002334564,0.0003746371,0.0001048358,0.0002312772,0.00004001021],"domain_scores_gemma":[0.996469,0.002069368,0.0008099979,0.00005132832,0.0005293198,0.00007100426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002067059,0.0000369365,0.000526936,0.4018661,0.001497775,0.0002312485,0.0002569111,0.0001772342,0.0008413956,0.0006488573,0.01544742,0.5782624],"study_design_scores_gemma":[0.0001859132,0.0004552454,0.007764369,0.3382904,0.0169741,0.003217997,0.0005276398,0.0001674452,0.0008944515,0.00117745,0.630268,0.00007692772],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001555695,0.9995161,0.00002188746,0.0001093213,0.00004240798,0.000005991361,0.00003524833,0.00000217965,0.0001112656],"genre_scores_gemma":[0.0009533546,0.9986524,0.0001084842,0.0001508338,0.00003384638,0.000009492023,0.00004160081,0.000001013332,0.00004890744],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005987103,"threshold_uncertainty_score":0.01206392,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09861715029883955,"score_gpt":0.4469495262259395,"score_spread":0.3483323759270999,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}